Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics
Protein Science · 2024
DOI: 10.1002/pro.5141 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Protein Science, 2024. Verfasst von Claiborne W Tydings und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: ErbB Receptors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
The epidermal growth factor (EGF) receptor (EGFR) is activated by the binding of one of seven EGF‐like ligands to its ectodomain. Ligand binding results in EGFR dimerization and stabilization of the active receptor conformation subsequently leading to activation of downstream signaling. Aberrant activation of EGFR contributes to cancer progression through EGFR overexpression/amplification, modulation of its positive and negative regulators, and/or activating mutations within EGFR. EGFR targeted therapeutic antibodies prevent dimerization and interaction with endogenous ligands by binding the ectodomain of EGFR. However, these antibodies have had limited success in the clinic, partially due to EGFR ectodomain resistance mutations, and are only applicable to a subset of patients with EGFR‐driven cancers. These limitations suggest that alternative EGFR targeted biologics need to be explored for EGFR‐driven cancer therapy. To this end, we analyze the EGFR interfaces of known inhibitory biologics with determined structures in the context of endogenous ligands, using the Rosetta macromolecular modeling software to highlight the most important interactions on a per‐residue basis. We use this analysis to identify the structural determinants of EGFR targeted biologics. We suggest that commonly observed binding motifs serve as the basis for rational design of new EGFR targeted biologics, such as peptides, antibodies, and nanobodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.
- Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA.
- Department of Medicine - Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, USA.
- Department of Medicine - Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Claiborne W Tydings, Bhuminder Singh, Adam W Smith, Kaitlyn V Ledwitch, Benjamin P Brown, Christine M Lovly, Allison S Walker, Jens Meiler
Förderung
- NIGMS NIH HHS
- NIDDK NIH HHS
- NIH HHS
- National Science Foundation
- National Institutes of Health
Zitieren
APA
Tydings, C. W., Singh, B., Smith, A. W., Ledwitch, K. V., Brown, B. P., Lovly, C. M., Walker, A. S., & Meiler, J. (2024). Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics. Protein Science. https://doi.org/10.1002/pro.5141
Vancouver
Tydings CW, Singh B, Smith AW, Ledwitch KV, Brown BP, Lovly CM, et al. Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics. Protein Science. 2024. doi:10.1002/pro.5141
BibTeX
@article{Tydings2024,
author = {Tydings, Claiborne W and Singh, Bhuminder and Smith, Adam W and Ledwitch, Kaitlyn V and Brown, Benjamin P and Lovly, Christine M and Walker, Allison S and Meiler, Jens},
title = {Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics},
journal = {Protein Science},
year = {2024},
doi = {10.1002/pro.5141}
}
EUVIMED